Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period

A. Lauro, A. Amaduzzi, A. Dazzi, G. Ercolani, C. Zanfi, L. Golfieri, G. L. Grazi, M. Vivarelli, M. Cescon, G. Varotti, M. Del Gaudio, M. Ravaioli, A. Siniscalchi, S. Faenza, A. D'Errico, M. Di Simone, L. Pironi, A. D. Pinna

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Induction therapy has been recently adopted for intestinal transplant. Patients and methods: We compared during first 30 days post-transplantation 29 recipients, allocated in two groups, treated with Daclizumab (Zenapax®) or Alemtuzumab (Campath-1H®). Results: During first month, 45% of Daclizumab recipients experienced six acute cellular rejections (ACRs) of mild degree, while 63% of them developed an infection requiring treatment. We found three acute cellular rejections in 17.6% of Alemtuzumab recipients, two with moderate degree; 64.7% of them required treatment for infection. Discussion and conclusions: Graft and patient 3-years cumulative survival rate were not significantly different between groups. Alemtuzumab seems to offer a better immunosuppression during first month.

Original languageEnglish
Pages (from-to)253-256
Number of pages4
JournalDigestive and Liver Disease
Volume39
Issue number3
DOIs
Publication statusPublished - Mar 2007

Keywords

  • Alemtuzumab
  • Daclizumab
  • Immunosuppression
  • Induction therapy

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period'. Together they form a unique fingerprint.

Cite this